ClinicalTrials.gg
RecruitingNCT07383246CAST-MTCUpdated Feb 3, 2026

CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC

A Phase 3 interventional study of 68Ga-CTR-FAPI PET-CT guided surgery and investigator choice of surgery in Medullary Thyroid Carcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Aug 2025, registered Jan 2026).
  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Carcinoma, Medullary with a site in China — 9 open to participants now, 11 under way, 2 of them phase 3. Carcinoma, Medullary · China.

Planned enrollment
9th of 16
150 · median 151
Started
2025
with 1 other
Phase 3
3 of 18
1 open now
Primary completion
2028-09
later than 10 of 10 live
Registered
16th of 18
by date
Lead sponsor
2 of 18
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Among the 18 studies in Carcinoma, Medullary with a site in China, this one is the 9th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 3, reaches primary completion later than 10 of the 10 other live ones, and was the 16th registered.

Carcinoma, Medullary

144 studies on the registry are indexed under Carcinoma, Medullary; 30 are open to participants now.

Browse Carcinoma, Medullary studies →

Open to participants now

9 of the 18 studies in Carcinoma, Medullary with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 16 Carcinoma, Medullary studies recruiting now, 9 (56%) set no upper age limit and 3 (19%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Carcinoma, Medullary with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label, non-inferiority Phase III clinical trial, aims to compare 68Ga-CTR-FAPI PET-CT-guided surgery to investigator-chosen surgical approaches to evaluate its efficacy in treating newly diagnosed medullary thyroid carcinoma. This study plans to enroll 150 newly diagnosed MTC patients, who will be randomly assigned in a 2:1 ratio to the experimental group (surgery based on 68Ga-CTR-FAPI PET-CT findings) and the control group (surgery based on the investigator's choice). The primary endpoint is the biochemical cure rate, with secondary endpoints including the biochemical cure rate in the R0 resection subgroup, the unnecessary dissection rate in the biochemical-cured subgroup, 3-year recurrence-free survival, the rate of change in surgical extent, and diagnostic accuracy.

Read the detailed description

Medullary thyroid carcinoma (MTC) is a relatively difficult-to-treat malignant thyroid tumor with a wide range of metastases. Surgery is the only curative treatment, and accurate assessment of the extent of metastatic disease is crucial for planning the surgical extent. Conventional imaging modalities have limited utility in fully evaluating the extent of MTC involvement. The tumor microenvironment of MTC is rich in cancer-associated fibroblasts (CAFs), which highly express fibroblast activation protein (FAP), whereas normal tissue fibroblasts express little to no FAP. Given the co-localization relationship between MTC cells and CAFs, fibroblast activation protein inhibitors (FAPIs) targeting FAP can be used to localize MTC lesions. The molecular probe CTR-FAPI, developed through covalent modification, improved the detection rate and diagnostic accuracy for MTC, providing a theoretical basis for performing precise surgery for MTC based on the extent of disease revealed by 68Ga-CTR-FAPI PET-CT.

This is a multicenter, randomized, open-label, two-arm, non-inferiority Phase III clinical trial. This study plans to enroll 150 newly diagnosed MTC patients, who will be randomly assigned in a 2:1 ratio to the experimental group (surgery based on 68Ga-CTR-FAPI PET-CT findings) and the control group (surgery based on the investigator's choice).

The study hypothesizes that CTR-FAPI-guided surgery can identify and resect more positive lesions while avoiding prophylactic dissection of disease-free areas, thereby benefiting patients. Proving the benefit of the former requires complete resection of all positive lesions. However, due to the frequent local invasion and adhesions associated with MTC lesions, achieving R0 resection is difficult in some patients. Therefore, the primary objective is to demonstrate that CTR-FAPI-guided surgery is non-inferior to the investigator's choice in IIT population. The primary endpoint was biochemical cure rate at 1-month post-surgery, defined by normalization of serum calcitonin levels. This parameter represents the strictest curative level for MTC and correlates with survival outcomes. In a nationwide retrospective analysis involving 863 patients, the 10-year overall survival (OS) of biochemical-cured MTC was 97.7%; in comparison, the 10-year OS of non-cured MTC was 70.3%.

The secondary objectives are to demonstrate its superiority in the subgroup achieving R0 resection, and to show that it avoids unnecessary lateral neck/upper mediastinum dissection in the subgroup achieving biochemical-cure. Key secondary endpoints include: the biochemical cure rate at 1 month post-surgery in the R0 resection subgroup, and the unnecessary dissection rate in the biochemical-cured subgroup, which address the two important secondary objectives and the study hypothesis. Other secondary endpoints include: 3-year recurrence-free survival, the rate of surgical plan modification in the experimental group, and the diagnostic accuracy of different imaging modalities for MTC lesions.

03

Conditions studied

  • Medullary Thyroid Carcinoma

Browse trials for

Keywords

  • Medullary Thyroid Cariconma
  • Surgery
  • CTR-FAPI
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly-diagnosed medullary thyroid carcinoma meeting either criterion a or criteria b + c:

    1. or cytologically confirmed diagnosis;
    2. Elevated serum calcitonin level (>10 pg/mL);
    3. Other infectious or neoplastic diseases excluded.
  • ≥ 12 weeks;
  • performance status of 0 or 1;
  • Absence of distant confirmed by conventional imaging, with resectable locoregional disease;
  • Scheduled to undergo surgery within 30 days;
  • Females of must use effective (e.g., sterilization, intrauterine device, condoms, oral/injectable contraceptives, abstinence, or partner vasectomy) during the study and for 6 months after study completion. Male participants must agree to use effective contraception during the same period;
  • Capable of understanding and voluntarily signing the form with good compliance.

Exclusion criteria

Exclusion Criteria:

  • History of prior treatment for medullary thyroid carcinoma (e.g., surgery, radiotherapy, targeted therapy, radionuclide therapy, or interventional therapy).
  • Major organ dysfunction, defined as:

    1. Bone marrow impairment: WBC ≤ 4.0×10⁹/L or neutrophils ≤ 1.5×10⁹/L; ≤ 100×10⁹/L; ≤ 90 g/L
    2. Hepatic impairment: PT or ≥ 1.5 × ; total ≥ 1.5 × ULN; /AST ≥ 2.5 × ULN (or ≥ 5 × ULN in participants with liver ); ALP ≥ 2.5 × ULN (or ≥ 4.5 × ULN in cases with bone or liver metastases)
    3. Renal impairment: BUN ≥ 1.5 × ULN; serum creatinine ≥ 1.5 × ULN
  • Women who are planning pregnancy, currently pregnant, or breastfeeding.
  • History of other malignant tumors;
  • Inability to lie flat for at least 30 minutes;
  • Known allergy to contrast agents;
  • Claustrophobia or other psychiatric disorders that may preclude compliance with study procedures;
  • Unwillingness to participate in the clinical trial;
  • Assessed as not being a surgical candidate or refusal to undergo surgery;
  • Any other condition deemed by the investigator to make the participant unsuitable for the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    ⁶⁸Ga-CTR-FAPI PET-CT guided surgery

    The participants assigned to the experimental arm will undergo ⁶⁸Ga-CTR-FAPI PET-CT imaging. The surgical extent will be determined by ⁶⁸Ga-CTR-FAPI PET-CT image.

    Procedure: 68Ga-CTR-FAPI PET-CT guided surgery

  • Active comparator
    investigator choice of surgery

    Since there is currently no standardized surgical extent for medullary thyroid carcinoma, the surgical approach for the control group will be determined by the attending surgeon, based on routine preoperative evaluation.

    Procedure: investigator choice of surgery

Interventions

  • Procedure68Ga-CTR-FAPI PET-CT guided surgery

    The participant will be intravenously administered with \[68Ga\]Ga-CTR-FAPI and undergo PET-CT imaging.The surgical extent will be determined by \[68Ga\]Ga-CTR-FAPI PET-CT image. The minimum extent of resection is total thyroidectomy plus central neck dissection. Therapeutic dissection of the lateral neck compartment and upper mediastinal lymph nodes within standard boundaries is performed, with the extent determined based on CTR-FAPI findings.

  • Procedureinvestigator choice of surgery

    Since there is currently no standardized surgical extent for medullary thyroid carcinoma, the surgical approach for the control group will be determined by the attending surgeon. Including but not limited to: Surgery based on conventional imaging (ultrasound/CT); Prophylactic neck dissection; Surgery based on tumor size, germline RET mutation status, and state of central lymph node metastasis; Surgery based on intraoperative frozen section findings.

06

What researchers measure

Primary outcomes

  1. Biochemical cure rate

    Biochemical cure is defined as postoperative serum calcitonin level less than 10pg/ml

    Time frame: 1 month after surgery

Secondary outcomes

  1. Biochemical cure rate in R0 resection subgroup

    Biochemical cure is defined as postoperative serum calcitonin level less than 10pg/ml. The outcome is assessed in the R0 resecton subgroup.

    Time frame: 1 month after surgery

  2. Unnecessary dissection rate in the biochemical cured subgroup

    The unnecessary dissection rate is defined as the proportion of patients whose dissections outside the central compartment yield no metastatic lymph nodes. This outcome will be evaluated exclusively in the biochemically cured subgroup, as only surgeries that achieve biochemical cure are considered to have an adequate surgical extent. In these patients, any dissection that yields negative specimens is deemed unnecessary. We anticipate that CTR-FAPI imaging will enable precise surgical planning, allowing for a more reduced extent of dissection compared to prophylactic surgery, thus minimizing complications.

    Time frame: 1month after surgery (after pathogoly report issued)

  3. Recurrence-free survival

    Recurrence-free survival is defined as the peroid from the date of surgery until any recurrence revealed by structural imaging or any cause of death. The day of imaging examination will be regarded as the day of recurrence.

    Time frame: 3 years after surgery

  4. Change rate in the extent of surgery in the experimental arm

    Change rate in the extent of surgery compared to the investigator's chioce in the experimental arm. The investigator's chosen surgical extent will be documented preoperatively when the attending doctor is not exposed to the CTR-FAPI findings.

    Time frame: immedaite after surgery

  5. Diagnostic accuracy rate

    Diagnostic accuracy is defined as the proportion of correctly diagnosed lesions (including both positive and negative) to the total number of lesions documented. It will be calculated separately for different imaging modalities (CTR-FAPI PET-CT, ultrasound, and CT).

    Time frame: 1 month after surgery (after pathology report issued)

07

Study locations

1 of 1 sites recruiting
  • National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, Beijing Municipality 10005, China
    Recruiting
08

References and documents

Publications

  • Kong Z, Li Z, Cui XY, Wang J, Xu M, Liu Y, Chen J, Ni S, Zhang Z, Fan X, Huang J, Lin Y, Sun Y, He Y, Lin X, Meng T, Li H, Song Y, Peng B, An C, Gao C, Li N, Liu C, Zhu Y, Yang Z, Liu Z, Liu S. CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma. Cancer Discov. 2025 Feb 7;15(2):316-328. doi: 10.1158/2159-8290.CD-24-0897. PubMed 39470165 ↗
  • Cui XY, Li Z, Kong Z, Liu Y, Meng H, Wen Z, Wang C, Chen J, Xu M, Li Y, Gao J, Zhu W, Hao Z, Huo L, Liu S, Yang Z, Liu Z. Covalent targeted radioligands potentiate radionuclide therapy. Nature. 2024 Jun;630(8015):206-213. doi: 10.1038/s41586-024-07461-6. Epub 2024 May 22. PubMed 38778111 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Sep 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 3, 2026
StartActual
Aug 25, 2025
Primary completionEst.
Sep 1, 2028
CompletionEst.
Dec 31, 2031
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07383246
Responsible party
SHAOYAN LIU (Director of Head and Neck Surgery, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Principal investigator
First posted
Feb 3, 2026
Start date
Aug 25, 2025
Primary completion
Sep 1, 2028 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Feb 3, 2026

Study contacts

Ziren Kong, MD
Contact
kongziren@pumc.edu.cn
0086-18500487274
Shaoyan Liu, MD
principal investigator · Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion